[go: up one dir, main page]

LT3129019T - MEDICAL USE OF ARTEMISININE COMPOUNDS AND GEFIRIN AGONISTS - Google Patents

MEDICAL USE OF ARTEMISININE COMPOUNDS AND GEFIRIN AGONISTS

Info

Publication number
LT3129019T
LT3129019T LT15717842T LT15717842T LT3129019T LT 3129019 T LT3129019 T LT 3129019T LT 15717842 T LT15717842 T LT 15717842T LT 15717842 T LT15717842 T LT 15717842T LT 3129019 T LT3129019 T LT 3129019T
Authority
LT
Lithuania
Prior art keywords
gefirin
artemisinine
agonists
compounds
medical use
Prior art date
Application number
LT15717842T
Other languages
Lithuanian (lt)
Inventor
Jin Li
Stefan Kubicek
Original Assignee
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh filed Critical Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh
Publication of LT3129019T publication Critical patent/LT3129019T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507Pancreatic cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • G01N33/9426GABA, i.e. gamma-amino-butyrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LT15717842T 2014-04-11 2015-04-09 MEDICAL USE OF ARTEMISININE COMPOUNDS AND GEFIRIN AGONISTS LT3129019T (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14164471.6A EP2929881A1 (en) 2014-04-11 2014-04-11 Medical use of artemisinin compounds and gephyrin agonists
PCT/EP2015/057755 WO2015155303A2 (en) 2014-04-11 2015-04-09 Medical use of artemisinin compounds and gephyrin agonists

Publications (1)

Publication Number Publication Date
LT3129019T true LT3129019T (en) 2019-11-11

Family

ID=50513025

Family Applications (1)

Application Number Title Priority Date Filing Date
LT15717842T LT3129019T (en) 2014-04-11 2015-04-09 MEDICAL USE OF ARTEMISININE COMPOUNDS AND GEFIRIN AGONISTS

Country Status (23)

Country Link
US (1) US9999621B2 (en)
EP (2) EP2929881A1 (en)
JP (1) JP6680759B2 (en)
KR (1) KR20160136452A (en)
CN (1) CN106459079B (en)
AU (1) AU2015245523A1 (en)
BR (1) BR112016023607A2 (en)
CA (1) CA2945046A1 (en)
CY (1) CY1122185T1 (en)
DK (1) DK3129019T3 (en)
ES (1) ES2749074T3 (en)
HR (1) HRP20191795T1 (en)
HU (1) HUE046397T2 (en)
IL (1) IL248259A0 (en)
LT (1) LT3129019T (en)
MX (1) MX2016013323A (en)
PL (1) PL3129019T3 (en)
PT (1) PT3129019T (en)
RS (1) RS59476B1 (en)
RU (1) RU2016144173A (en)
SI (1) SI3129019T1 (en)
SM (1) SMT201900560T1 (en)
WO (1) WO2015155303A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107349198A (en) * 2016-05-10 2017-11-17 复旦大学 Artemether is preparing the purposes in promoting lipolysis and improving glycometabolism preparation
CN108341829B (en) * 2016-12-09 2020-01-24 新乡学院 Artemisinin ester compound with cardiovascular and cerebrovascular disease prevention and treatment activity, preparation method and application thereof
EP3558299B1 (en) * 2016-12-20 2025-02-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Artesunate for the treatment of neurodegeneration with brain iron accumulation
WO2019153325A1 (en) * 2018-02-12 2019-08-15 深圳市中医院 Application of artemisinin derivative in preparation of medicament for preventing and treating type 2 diabetes and complications thereof, and pharmaceutical composition
CN108403686A (en) * 2018-02-12 2018-08-17 深圳市中医院 Application and pharmaceutical composition of the artemisinin derivative in preparing prevention and treatment diabetes B and its complication medicine
CN108354927A (en) * 2018-03-29 2018-08-03 上海壹志医药科技有限公司 The new pharmaceutical uses of arteether
CN109331012A (en) * 2018-11-02 2019-02-15 广州中医药大学(广州中医药研究院) Application of artemisinin derivatives in the preparation of antiepileptic drugs
CN110200980B (en) * 2019-05-13 2022-07-12 华南师范大学 Oral nanoparticles of artemisinin-loaded citrus pectin
CN110938080A (en) * 2019-08-15 2020-03-31 恩施硒禾生物科技有限公司 Preparation method of artesunate
KR102524408B1 (en) * 2020-08-19 2023-04-21 주식회사 노브메타파마 Pharmaceutical composition for preventing or treating type 2 diabetes mellitus containing amodiaquine and artesunate-based drug
EP4281066A2 (en) * 2021-01-20 2023-11-29 Cornell University Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease
CN114807015B (en) * 2022-05-20 2022-11-22 呈诺再生医学科技(北京)有限公司 Induction method for promoting islet alpha cells to be converted into beta cells and application thereof
CN118526484A (en) * 2024-07-26 2024-08-23 中国中医科学院中药研究所 Application of artesunate or dihydroartemisinin in preparation of preparation for improving adverse reaction of rosiglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362810B1 (en) * 1988-10-07 1993-05-05 Hoechst Aktiengesellschaft Antimalarial compositions using quinidine, artemisinine and its derivatives
EP1978028A1 (en) * 2007-04-05 2008-10-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of gene variants of the human MEIS1, BTBD9, MAP2K5, LBXCOR1, PTPRD or A2BP1 gene for diagnostic and therapeutic approaches to restless legs syndrome (RLS)
US20100151056A1 (en) * 2008-12-16 2010-06-17 Hanan Polansky Dietary supplements for decreasing the latent foreign dna load
CN101879158B (en) * 2010-07-01 2012-02-29 中国科学院广州生物医药与健康研究院 New applications of artemisinin derivatives
KR101277710B1 (en) * 2010-09-07 2013-06-24 연세대학교 산학협력단 Novel Artemisinin or Deoxoartemisinin-glycolipid Hybrid Derivatives and Antiangiogenic Use Thereof
WO2014007853A1 (en) * 2012-07-03 2014-01-09 The Regents Of The University Of California Dihydromyricetin for the treatment of diseases and disorders of the glutamatergic system
ES2666465T3 (en) * 2012-09-27 2018-05-04 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods to produce a population of pancreatic beta cells

Also Published As

Publication number Publication date
JP2017513936A (en) 2017-06-01
PL3129019T3 (en) 2020-01-31
RS59476B1 (en) 2019-12-31
CA2945046A1 (en) 2015-10-15
CY1122185T1 (en) 2020-11-25
PT3129019T (en) 2019-10-28
EP3129019A2 (en) 2017-02-15
SI3129019T1 (en) 2019-11-29
ES2749074T3 (en) 2020-03-19
HUE046397T2 (en) 2020-03-30
BR112016023607A2 (en) 2017-12-26
RU2016144173A3 (en) 2018-12-03
US9999621B2 (en) 2018-06-19
IL248259A0 (en) 2016-11-30
MX2016013323A (en) 2017-04-27
US20170027929A1 (en) 2017-02-02
CN106459079A (en) 2017-02-22
KR20160136452A (en) 2016-11-29
EP3129019B1 (en) 2019-07-17
RU2016144173A (en) 2018-05-11
WO2015155303A3 (en) 2016-02-04
WO2015155303A2 (en) 2015-10-15
JP6680759B2 (en) 2020-04-15
AU2015245523A1 (en) 2016-11-03
EP2929881A1 (en) 2015-10-14
HRP20191795T1 (en) 2019-12-27
SMT201900560T1 (en) 2019-11-13
DK3129019T3 (en) 2019-10-07
CN106459079B (en) 2019-09-24

Similar Documents

Publication Publication Date Title
HUE046000T2 (en) Antiproferative Compounds and Methods of Use
IL250415B (en) Anti-pdl- antibodies and methods of use thereof
HUE046756T2 (en) Benzoxazepine-oxazolidinone compounds and methods of their use
LT3129019T (en) MEDICAL USE OF ARTEMISININE COMPOUNDS AND GEFIRIN AGONISTS
EP3338783C0 (en) ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES
PT3548033T (en) COMPOUNDS AND THEIR METHODS OF USE
DK3197354T3 (en) MEDICAL DEVICE
LT3099717T (en) ANTICON MOLECULES FOR TIM-3-CHIAM AND THEIR USE
LT3331877T (en) PYRAZOLPYRIMIDINE DERIVATIVES AND THEIR USE
DK3202305T3 (en) DISPOSABLE ENDOSCOPE AND SYSTEM
IL251246A0 (en) Therapeutically active compounds and their methods of use
SI3218005T1 (en) Glycan-interacting compounds and methods of use
LT3102555T (en) COMPOSITIONS AND THEIR USE
LT3341027T (en) TRANSFECTION COMPLEXES AND METHODS OF THEIR USE
HUE050761T2 (en) Compounds and methods of use
BR112016020889A2 (en) hppd variants and methods of use
IL283335B (en) Dihydropyrimidin-2-one compounds and medical use thereof
HUE045025T2 (en) Heterobicyclic compounds and their use in the treatment of tuberculosis
DK3137126T3 (en) Medical devices with non-uniform coatings for improved echogenicity
EP3007770A4 (en) MEDICAL ROBOT
ZA201606450B (en) Compounds and their methods of use
DK2913034T3 (en) Surgical handpiece
GB201403697D0 (en) Compounds and methods of use
LT3548092T (en) RMD COMPOSITION AND METHODS OF USE
LT3518927T (en) 1-PHENYLPROPANONE COMPOUNDS AND THEIR USE